Due to the low prevalence of uterine sarcomas, most data on prevalence and risk factors are derived from case histories or retrospective trials with low numbers.
The onus remains, therefore, on undertaking clinical trials with low risk of bias and focusing on consistent and relevant outcomes [11].
However, just 6% (i.e., absolute number = 2) of articles were considered level 2 (i.e., randomized controlled trials with low risk of bias) (Fig. 2) [54] 54].
Trials with low power are unlikely to produce conclusive results, but their findings can be used by pooling then in a meta-analysis.
a grade B recommendation is based on a scientific presumption provided by studies with an intermediate level of proof, such as randomised, comparative trials with low power, cohort studies, well-conducted non-randomised comparative studies or cohort studies.
(ii) a grade B recommendation is based on a scientific presumption provided by studies with an intermediate level of proof, such as randomised, comparative trials with low power, cohort studies, well-conducted non-randomised comparative studies or cohort studies.
However, such an analysis may be biased, because trials with low power are likely to have a nonsignificant result and are less likely to be published than trials with a statistically significant outcome.
Another important review provided an unclear conclusion because it included trials with low quality [20].
Randomized trials with low risk of systematic errors and low risk of random errors are needed.
Correct trials with low confidence ratings are likely to be guesses.
Randomized trials with low risk of systematic errors (bias) and low risk of random errors (play of chance) are needed.
